Adaptive zone model predictive control with a glucose and velocity dependent dynamic cost function for an artificial pancreas
US-12128212-B2 · Oct 29, 2024 · US
US10137245B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10137245-B2 |
| Application number | US-201113817156-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 8, 2011 |
| Priority date | Aug 17, 2010 |
| Publication date | Nov 27, 2018 |
| Grant date | Nov 27, 2018 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
A monitoring and control system, apparatus and method for safe administration, reduction or cessation of administration of at least on medication, fluid or both, which includes at least one Central Source Site (CSS) Photoplethysmography (PPG) sensor coupled to means for control of delivery of the at least one medication, fluid or both.
Opening claim text (preview).
What is claimed is: 1. A system for monitoring and control for safe administration, reduction or cessation of administration of at least one of medication to a subject, comprising: (a) at least one photoplethysmography (PPG) sensor adapted to secure to a central source site of the subject; (b) an infusion pump for delivering the at least one medication to the subject, wherein the infusion pump comprises an infusion controller for increasing or decreasing flow of medication to the subject; and (c) an infusion pump agnostic safety device that is adapted to be deployed onto tubing adapted to deliver the at least one medication from the infusion pump to the subject, wherein the safety device comprises an occlusion apparatus and an occlusion controller, wherein the occlusion controller receives signals from the PPG sensor, calculates at least one respiratory parameter based on the signals from the PPG sensor, and if the at least one respiratory parameter is determined by the occlusion controller to be adverse, the occlusion controller directs the occlusion apparatus to partially or completely occlude the tubing wherein the infusion pump agnostic safety device only occludes the tubing in the event the occlusion controller determines that an adverse event has occurred. 2. The system of claim 1 , wherein the at least one respiratory parameter comprises respiratory rate, respiratory effort, or both. 3. The system of claim 1 , wherein the occlusion controller is further configured to initiate an alarm if the at least one respiratory parameter is determined by the occlusion controller to be adverse. 4. The system of claim 1 , further comprising at least one additional sensor. 5. The system of claim 4 , wherein the at least one additional sensor is selected from the group consisting of an electrocardiograph, a capnometer, a nasal pressure sensor and a nasal flow sensor. 6. The system of claim 4 , wherein the occlusion controller sends signals to the occlusion apparatus to partially or completely occlude the tubing if an adverse parameter based on signals from the at least one additional sensor is detected. 7. The system of claim 1 , wherein the infusion pump is a patient controlled anaesthesia (PCA) pump. 8. The system of claim 1 , wherein the medication comprises at least one of an opioid, a benzodiazepine and propofol. 9. The system of claim 1 , further comprising ventilation means for applying positive ventilation pressure to the subject upon receipt by the ventilation means of a control signal to initiate, increase or decrease ventilation. 10. The system of claim 9 , wherein the control signal to initiate, increase or decrease ventilation is given to the ventilation means from the occlusion controller when at least one adverse respiratory parameter is determined by the controller. 11. The system of claim 1 , wherein the central source site of the individual is the nasal septum or the nasal alar.
Measuring pulse rate or heart rate · CPC title
Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition · CPC title
with means for measuring the humidity · CPC title
Sleep apnoea · CPC title
Head-worn items, e.g. helmets, masks, headphones or goggles · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.